Ablynx initiates Phase IIb anti-RSV nanobody trial for infants
12 January 2017 | By Niamh Marriott, Digital Editor
Topline results from this Phase IIb study to treat children with RSV with inhaled ALX-0171 are expected in the second half of 2018...
List view / Grid view
News
BioPharma leaders call for gender diversity
12 January 2017 | By Niamh Marriott, Digital Editor
More than 100 prominent life sciences executives, investors, and business leaders have signed an open letter calling on the industry to increase gender diversity...
NICE approves former CDF kidney cancer drug for NHS use
12 January 2017 | By Niamh Marriott, Digital Editor
Everolimus (Afinitor, Novartis) is now recommended to be available on the NHS as a treatment option for some patients with advanced renal cell carcinoma...
Phase II trial for F2G’s antifungal drug following EU approval
11 January 2017 | By Niamh Marriott, Digital Editor
F901318 is the first member of a novel class of systemic antifungal agents targeting life threatening mould infections and acting through a target...
NHS Confederation appoints Niall Dickson as new Chief Executive
11 January 2017 | By Niamh Marriott, Digital Editor
The NHS Confederation today announced the appointment of Niall Dickson as its new Chief Executive.
Dolomite Bio launches Injection Valve and Sample Loop for scRNA-Seq
10 January 2017 | By Dolomite Bio
Dolomite Bio has launched a new Injection Valve and Sample Loop for single cell RNA sequencing workflows...
Put it to the test
10 January 2017 | By Charles Ischi AG | Kraemer Elektronik
EPM talks to Charles Ischi about the best approach to selecting testing equipment for oral solid dosage applications...
Novartis invests in Ionis’ therapies to reduce cardiovascular risk
10 January 2017 | By Niamh Marriott, Digital Editor
Novartis announced a collaboration and option agreement with Ionis Pharmaceuticals and its affiliate Akcea Therapeutics to license two novel treatments with the potential to significantly reduce cardiovascular risk in patients suffering from high levels of lipoproteins known as Lp(a) and ApoCIII.
FDA approves Roche’s assay to assess ovarian reserve
10 January 2017 | By Niamh Marriott, Digital Editor
The blood test produces standardised results for assessing ovarian reserve as compared with the use of vaginal ultrasound...
Aridis’ human monoclonal antibody pneumonia trial a safe success
9 January 2017 | By Niamh Marriott, Digital Editor
AR-301 (Salvecin) is a fully human monoclonal IgG1 antibody that specifically targets S. aureus alpha-toxin and protects host cells from destruction...
Amorsa to collaborate with J&J on treatment-resistant depression therapy
5 January 2017 | By Niamh Marriott, Digital Editor
Amorsa has announced a research, option and license agreement with Janssen to develop and commercialise a novel small molecule drug candidate for depression...
FDA to review 3 new diabetes drugs that reduce cardiovascular death risk
5 January 2017 | By Niamh Marriott, Digital Editor
In the trial, empagliflozin significantly reduced the relative risk of the combined primary endpoint of cardiovascular death, non-fatal heart attack by 14%...
Enterome starts Phase I Crohn’s disease trial
5 January 2017 | By Niamh Marriott (Digital Editor)
Enterome has launched a Phase I clinical study with its lead drug candidate EB8018, a small molecule designed to block FimH, to treat Crohn’s disease...
Vtesse appoints Jason Meyenburg as Chief Commercial Officer
4 January 2017 | By Niamh Louise Marriott, Digital Editor
Meyenburg joins the company from Alexion Pharmaceuticals, where he most recently served as Senior Vice President of Commercial Operations.
Sanofi’s insulin injection Soliqua 100/33 now available in US
4 January 2017 | By Niamh Louise Marriott, Digital Editor
It is indicated for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin (less than 60 Units daily) or lixisenatide...
